In this regard, a shift of the secretome from a tumor suppressive (driven by wt-p53) to a cancer-promoting one has been described in models of p53 loss of function (LOF), dominant-negative (DN) inhibition by mutant p53 or gain of neomorphic functions (GOF) [36–38]. The gene discussed is TP53; the disease is cancer.